Predictive Value of Anti‐ SMN Complex Antibodies for Monitoring Cardiopulmonary Complications in MCTD : Insights From an ELISA Study Using Recombinant Gemin4 and an Anti‐Nuclear Antibody Test
- 21 January 2025
- journal article
- letter
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70089
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the diseaseImmunological Medicine, 2024
- ELISA detection of anti-eIF2B antibodies in Japanese patients with systemic sclerosisRheumatology, 2023
- Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue diseaseRheumatology, 2023
- Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumoniaRheumatology, 2021
- 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseasesModern Rheumatology, 2020
- Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohortsClinica Chimica Acta, 2017
- Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteinsArthritis & Rheumatism, 2011